SMARCB1 and lung carcinoma: The authors compared transcriptomic profiles of unclassified thoracic sarcomas showing SMARCA4 inactivation with those of SMARCA4-mutated small-cell carcinomas of the ovary, hypercalcemic type (SCCOHTs), SMARCB1-inactivated malignant rhabdoid tumors (MRTs), and lung carcinomas (of which 5–10% has SMARCA4 mutations) [1].